Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Clinical trial NCT05858983 · RECRUITING

Trial details

NCT number: NCT05858983
Sponsor: Frontera Therapeutics
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Biallelic RPE65 Mutation-associated Retinal Dystrophy

Start date: 2022-11-30
Primary completion: 2025-11-30
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.